SML0248
Zolmitriptan
≥98% (HPLC)
동의어(들):
(4S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone, (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone, 311C90
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C16H21N3O2
CAS 번호:
Molecular Weight:
287.36
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
SMILES string
CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12
InChI key
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -3 to -8°, c = 1 in methanol
color
white to beige
solubility
DMSO: ≥5 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... HTR1B(3351), HTR1D(3352)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
Application
Zolmitriptan has been used as a 5-hydroxytryptamine receptor 1B (5-HT1B/D) activator to treat grafts to study its effects on the morphology of the ectopic eye.
Zolmitriptan has been used to induce hyper-innervation of transplants.
Biochem/physiol Actions
Zolmitriptan is a potent, selective. centrally and peripherally acting 5HT1B/1D receptor agonist.
Zolmitriptan is a selective serotonin receptor agonist of the 5HT1B and 5HT1D subtypes, both centrally and peripherally. It has been used clinically for the acute treatment of migraine attacks with or without aura and cluster headaches.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
David W Dodick et al.
Cephalalgia : an international journal of headache, 31(3), 296-300 (2010-10-13)
Endpoints used to evaluate the efficacy of acute anti-migraine drugs do not measure the tolerability. Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire. The
Ziya Bayrak et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 78(3), 499-505 (2011-03-01)
First-pass metabolism can be overcome by sublingual drug delivery, and quick drug entry into the systemic circulation can be obtained. In certain diseases such as migraine therapy, taking fast pharmacological response is an important criteria. In this study, zolmitriptan sublingual
Michal Douša et al.
Journal of pharmaceutical and biomedical analysis, 58, 1-6 (2011-10-11)
A new impurity was detected and determined using gradient ion-pair UHPLC method with UV detection in zolmitriptan (ZOL). Using MS, NMR and IR study the impurity was identified as (4S,4'S)-4,4'-(2,2'-(4-(dimethylamino)butane-1,1-diyl)bis(3-(2-(dimethylamino) ethyl)-1H-indole-5,2-diyl))bis(methylene)di(oxazolidin-2-one) (ZOL-dimer). The standard of ZOL-dimer was consequently prepared via
Peter J Goadsby et al.
Headache, 46(1), 138-149 (2006-01-18)
Migraine is a common disabling neurological disorder, associated with headache, nausea, and on occasions vomiting. Zolmitriptan is a widely available serotonin 5HT(1B/1D) receptor agonist with a long track record in clinical studies and in the treatment of acute migraine. A
B Lee Peterlin et al.
Expert opinion on drug metabolism & toxicology, 3(6), 899-911 (2007-11-22)
Migraine is a common, often disabling, neurovascular disease that has been shown to be associated with abnormal serotonergic activity. Drugs that modulate serotonin receptors are commonly used in the acute treatment of a migraine attack. Zolmitriptan, a 5-hydroxytryptophan(1B/1D) receptor agonist
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.